Sign in
Not yet recruitingPhase 3

COPE-CP: The effect of Celecoxib on pain, quality of life, use of opioids, and inflammation in patients suffering from chronic pancreatitis

Key facts

Who runs it
Odense University Hospital
Where
Denmark3 sites in 1 countryChoose a country to see its sites
Status
Not yet recruiting
Phase
Phase 3
People taking part
80 people, planned
Starts
1 Dec 2026
Expected to end
29 Oct 2028
Type of study
Interventional
Record updated
25 September 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Age: Male or female individuals aged >= 18 years
  • Diagnosis: Confirmed diagnosis of Chronic Pancreatitis (CP) according to the HaPanEU guidelines, established >= 6 months prior to screening
  • Pain Status: Symptomatic CP with a mean pain intensity >= 4 and <= 9 on a Numeric Rating Scale (NRS, 0-10) during the last 6 months
  • Renal Function: Plasma creatinine within normal local laboratory reference range at the time of screening
  • Contraception: For females of childbearing potential: Willingness to use a highly effective method of contraception (failure rate < 1% per year) throughout the treatment period
  • Communication: Ability to understand, read, and speak Danish to ensure reliable completion of Patient Reported Outcomes (PROs)
  • Compliance: The investigator assesses that the participant is capable of understanding the trial requirements and is expected to comply with all study procedures
  • Informed Consent: Ability to provide written informed consent prior to any study-related procedures

Who cannot take part

  • Recent Acute Pancreatitis: Diagnosed with acute pancreatitis requiring hospitalization within 4 weeks prior to screening
  • Prior NSAID Use: Use of any Non-Steroidal Anti-Inflammatory Drug (NSAID) within 30 days prior to screening
  • Prohibited Medication: Current use of ACE-inhibitors, Angiotensin-II-receptor blockers, Direct Oral Anticoagulants (DOACs), or Acetylsalicylic acid
  • Hypersensitivity: Known allergy or hypersensitivity to Celecoxib, sulfonamides, or other NSAIDs (including history of NSAID-induced asthma or urticaria)
  • Gastrointestinal Disease: History of peptic ulcer, gastrointestinal hemorrhage, or active inflammatory bowel disease (IBD)
  • Renal or Hepatic Impairment: History of known chronic renal insufficiency, hepatic cirrhosis, or severe hepatic impairment
  • Established Cardiovascular Disease: History of heart failure (NYHA II-IV), coronary artery disease, angina pectoris, myocardial infarction, stroke, or transient ischemic attack (TIA)
  • General Safety Exclusion: Any other clinical condition or laboratory abnormality that, in the opinion of the investigators, makes the patient unsuitable for participation
  • Cardiovascular Risk (SCORE2): Moderate-to-high risk of cardiovascular disease assessed by SCORE2/SCORE2-OP tools exceeding: >5.0% (age 40-59), >7.5% (age 60-69), or >10% (age 70-75)
  • Pregnancy and Lactation: Confirmed or suspected pregnancy, planning of pregnancy during the treatment period, or breastfeeding

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The aim of this investigator-initiated, randomized, controlled trial in adult Danish patients suffering from chronic pancreatitis (CP) is to evaluate the effect of Celecoxib, an oral NSAID, compared with placebo during 16 weeks of treatment. The primary objective is to assess patient-reported pain and quality of life (QoL) measured by the Comprehensive Pain Assessment Tool Short Form for Chronic Pancreatitis (COMPAT-SF).

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
COPE-CP: The effect of Celecoxib on pain, quality of life, use of opioids, and inflammation in patients suffering from chronic pancreatitis: a multicenter randomized placebo-controlled, double-blinded clinical trial
Record updated
25 September 2026